Three vs. 10 days of amoxycillin–clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double- blind placebo-controlled trial Patricia van Velzen, MD, Gerben ter.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

J. R. Masclans, M. Pérez, J. Almirall, L. Lorente, A. Marqués, L

L. Boyanova Clinical Microbiology and Infection

Benchmarking inappropriate empirical antibiotic treatment

Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome J. Guinea, M. Torres-Narbona, P.

Sputum colour reported by patients is not a reliable marker of the presence of bacteria in acute exacerbations of chronic obstructive pulmonary disease

Susceptibility of Escherichia coli to the amoxycillin-clavulanate combination: which recommendations should be used to provide relevant information to.

Gut bacterial microbiota and obesity

Approach to diagnosis of infective endocarditis

Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones J. Mensa, A. Trilla

Cause‐specific long‐term mortality rates in patients recovered from community‐acquired pneumonia as compared with the general Dutch population A.H.W.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

J.-P. Van geertruyden Clinical Microbiology and Infection

Virological tools to diagnose and monitor hepatitis C virus infection

Three vs. 10 days of amoxycillin–clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study

Public health significance of invasive mosquitoes in Europe

Antimicrobial drug use and infection control practices associated with the prevalence of methicillin-resistant Staphylococcus aureus in European hospitals

E. Cambau, M. Drancourt Clinical Microbiology and Infection

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

V.E. Nambudiri, R.C. Dwyer, C.A. Camargo, T.S. Kupper, D.J. Pallin

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

Single-dose antibiotic prophylaxis for urinary catheter removal does not reduce the risk of urinary tract infection in surgical patients: a randomized.

Vector control: a cornerstone in the malaria elimination campaign

Commentary on Cochrane review of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children M. Jones, T. Jefferson,

Training for the infectious diseases speciality in Norway

G. Höffken Clinical Microbiology and Infection

Community-acquired pneumonia: the evolving challenge

Does it make sense to detect Streptococcus pyogenes during tonsillitis in Europe to prevent acute rheumatic fever? S. Edouard, A. Michel-Lepage, D. Raoult

A. Pan, R. Buttazzi, M. Marchi, C. Gagliotti, D. Resi, M.L. Moro

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Effects of gentamicin monotherapy for the initial treatment of community-onset complicated non-obstructive acute pyelonephritis due to Enterobacteriaceae.

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

Elements of design: the knowledge on which we build

Levofloxacin in the treatment of ventilator-associated pneumonia

G. Pappas Clinical Microbiology and Infection

Combating the spread of carbapenemases in Enterobacteriaceae: a battle that infection prevention should not lose P. Savard, T.M. Perl Clinical Microbiology.

Acute schistosomiasis, a diagnostic and therapeutic challenge

Metagenomics and probiotics

Effect of antioxidants on the immune response of Helicobacter pylori

Recent developments in staphylococcal scalded skin syndrome

The practice of travel medicine in Europe

Systematic review of antibiotic consumption in acute care hospitals

Abstracts cont. Clinical Microbiology and Infection

Abstracts cont. Clinical Microbiology and Infection

Benchmarking inappropriate empirical antibiotic treatment

P.M. Hawkey Clinical Microbiology and Infection

Current experience in treating invasive zygomycosis with posaconazole

Reducing antibiotic use in influenza: challenges and rewards

Fibronectin concentrations in catheter sepsis

Repeat lumbar puncture in adults with bacterial meningitis

H. Leblebicioglu, C. Eroglu Clinical Microbiology and Infection

Clinical infection services—the Leiden experience

V. Spoorenberg, J. M. Prins, B. C. Opmeer, T. M. de Reijke, M. E. J. L

Clinical Microbiology and Infection

Nebulized hypertonic saline treatment in hospitalized children with moderate to severe viral bronchiolitis Z. Luo, Z. Fu, E. Liu, X. Xu, X. Fu, D. Peng,

Sanford Chodosh Clinical Microbiology and Infection

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre R.R. Laffer, P. Graber, P.E. Ochsner, W. Zimmerli

Abstracts Clinical Microbiology and Infection

Modelling during an emergency: the 2009 H1N1 influenza pandemic

Carratalà J. Clinical Microbiology and Infection

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

New patterns of HIV-1 resistance during HAART

Impact of antibiotic restrictions: the patient's perspective

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

Three vs. 10 days of amoxycillin–clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study B.M. Roede, P. Bresser, R. El Moussaoui, F.H. Krouwels, B.T.J. van den Berg, P.M. Hooghiemstra, C.A.J.M. de Borgie, P. Speelman, P.M.M. Bossuyt, J.M. Prins Clinical Microbiology and Infection Volume 13, Issue 3, Pages 284-290 (March 2007) DOI: 10.1111/j.1469-0691.2006.01638.x Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 Trial profile (COPD, chronic obstructive pulmonary disease; co-amoxyclav, amoxycillin-clavulanic acid). Clinical Microbiology and Infection 2007 13, 284-290DOI: (10.1111/j.1469-0691.2006.01638.x) Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 2 Symptom scores for both treatment groups. The symptom scores of both treatment groups are expressed as medians and inter-quartile ranges. Day –30 represents the pre-exacerbation level; day 0 is the day of starting antibiotic therapy; day 21 is test of cure. Clinical Microbiology and Infection 2007 13, 284-290DOI: (10.1111/j.1469-0691.2006.01638.x) Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 3 Clinical success in the intention-to-treat population. Clinical Microbiology and Infection 2007 13, 284-290DOI: (10.1111/j.1469-0691.2006.01638.x) Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions